SEPT 9 (Septin 9) is encoded by the gene mapped to human chromosome 17q25. The encoded protein is colocalized with microtubules. Septin 9 belongs to the septin family and is highly expressed in lymphoid tissue.
Synonyms: Anti-AF17q25; Anti-KIAA0991; Anti-MSF; Anti-MSF1; Anti-PNUTL4; Anti-SeptD1; Anti-septin 9
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: Septin 9 (SEPT9) is involved in Rho signaling. It has an ability to regulate actin dynamics by interacting with the Rho effector rhotekin and inhibiting the Rho activator septin-associated-Rho guanine nucleotide exchange factor (SA-RhoGEF). The protein also plays a vital role in cell division. Septin 9 deficient cells fail to complete cytokinesis. Mutations in SEPT9 lead to hereditary neuralgic amyotrophy (HNA). Methylated SEPT9 DNA in plasma acts as a potential biomarker for the diagnosis of colorectal cancer.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC